Prolylcarboxypeptidase inhibitors
US9365539B2 · kind B2 · utility
1Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2011 |
| Grant date | Jun 14, 2016 |
| Priority date | — |
| Expiry date | Sep 19, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.